Stock 1952 EVEREST MEDICINES LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Everest Medicines Limited

Equities

1952

KYG3224E1061

Market Closed - Hong Kong S.E.
Other stock markets
 09:09:00 03/05/2024 BST 		5-day change 1st Jan Change
24.95 HKD -1.96% Intraday chart for Everest Medicines Limited +1.22% +19.38%
05-02 Everest Medicines Announces Hong Kong Department of Health Approval of Nefecon® for the Treatment for Primary IgA Nephropathy in Adult Patients CI
04-25 Everest Medicines' Loss Widens in 2023 MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Everest Medicines Announces Financial Results for Full Year Ended December 31, 2023
AQ
Everest Medicines Strengthens Management Team with Appointments of Chief Medical Officer and Chief Product Officer
AQ
Everest Medicines to Announce Full-Year 2023 Financial Results on March 28, 2024
AQ
Everest Medicines and Kezar Life Sciences Receive IND Approval from China NMPA for PALIZADE Trial in Lupus Nephritis
PR
Everest Medicines' Partner Pfizer Announces European Commission Approves VELSIPITY® for Patients with Moderately to Severely Active Ulcerative Colitis
PR
Everest Medicines Licensing Partner Venatorx Pharmaceuticals Announces Publication of Positive Results from Cefepime-Taniborbactam's Phase 3 CERTAIN-1 Study in New England Journal of Medicine
AQ
Calliditas Year-end report, January - December 2023
AQ
Everest Medicines Announces Termination of Collaboration Agreements with Providence
AQ
Everest Medicines Announces 2023 Revenue Expected to be Between RMB124 Million and RMB126 Million
AQ
Everest Medicines Partner Calliditas Therapeutics Announces Nefecon the Only FDA-approved Treatment for IgA Nephropathy to Significantly Slow Kidney Function Decline
AQ
Everest Medicines' Partner Calliditas Therapeutics Announces Nefecon® the Only FDA-approved Treatment for IgA Nephropathy to Significantly Slow Kidney Function Decline
PR
Everest Medicines Announces Acceptance of Nefecon New Drug Applications for the Treatment of Primary IgA Nephropathy in Adult Patients in South Korea
AQ
Calliditas partner Everest Medicines announces China NMPA's approval of Nefecon for the treatment of primary IgA nephropathy
AQ
Everest Medicines Announces China NMPA's Approval of Nefecon for the Treatment of Primary IgA Nephropathy in Adult Patients
AQ
Calliditas' partner Everest Medicines announces China NMPA's approval of Nefecon® for the treatment of primary IgA nephropathy
AQ
Everest Medicines Announces Poster Presentation at ASN Kidney Week on Nefecon Chinese Patient Data and to Hold Conference Calls
AQ
Everest Medicines Announces New Drug Application Approval by the Pharmaceutical Administration Bureau of Macau for Nefecon for the Treatment of Primary IgA Nephropathy
AQ
New Drug Application Approval by the Pharmaceutical Administration Bureau of Macau for Nefecon® for the Treatment of Primary IgA Nephropathy
AQ
Everest Medicines Partner Calliditas Presents New Data from the NefIgArd Phase 3 Trial at the 17th International Symposium on IgA Nephropathy Tokyo 2023
AQ
Everest Medicines' Partner Calliditas Presents New Data from the NefIgArd Phase 3 Trial at the 17th International Symposium on IgA Nephropathy Tokyo 2023
PR
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 1952 Stock
  4. News Everest Medicines Limited
  5. Press Releases